|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
524 S Main St, Suite 110, Ann Arbor, Michigan 48104, US
|
|
ONL Therapeutics (ONL) is a clinical stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions.
By advancing a novel breakthrough technology designed to protect photoreceptors against apoptotic and inflammatory cell death, ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing the death of retinal cells - the root cause of vision loss and the leading cause of blindness.
Based on its industry-leading expertise in photoreceptor protection, ONL is developing breakthrough treatments for serious, vision-threatening retinal diseases and conditions. Lead therapeutic candidate, ONL1204, is a first-in-class small molecule peptide initially being for the protection of photoreceptors in retinal detachment. Preclinical data to date for ONL1204 demonstrates the drug's ability to protect photoreceptors against the apoptosis process triggered by retinal detachment.
|
ONL Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used ONL Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact ONL Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.